BARDA Contract

BARDA Contract

In March 2011, Novavax was awarded a contract by the Office of Biomedical Advanced Research and Development Authority (BARDA) within the Office of the Assistant Secretary for Preparedness and Response (ASPR) at the U.S. Department of Health and Human Services (HHS) for the advanced clinical and manufacturing development of our seasonal and pandemic influenza virus-like particle (“VLP”) vaccine candidates. The advances in our seasonal influenza nanoparticle program have resulted in a natural conclusion of our activities under the HHS BARDA contract, which completed its term in September 2016.